Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Recruiting · NCT05455619 · Registry updated 2026-04-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | Insulin Resistance, Neoplasms by Site, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, glucose metabolism disease, hyperglycemia, hyperinsulinism, metabolic disease, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-04-22 | NCT05455619 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| SynDevRx, Inc. | 2 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 558 |
| Doctors Hospital of Laredo | Laredo | United States | 4 |
| Hoag Memorial Hospital Presbyterian | Newport | United States | 2 |
| Hope and Healing Cancer Services | Hinsdale | United States | 21 |
| Loma Linda University Cancer Center | Loma Linda | United States | 4 |
| Miami Cancer Institute at Baptist Health | Miami | United States | 3 |
| Penn State Milton S Hershey Medical Center | Hershey | United States | 9 |
| Sharp Healthcare | San Diego | United States | 2 |
| Trinity Health | Ypsilanti | United States | 3 |
| Vanderbilt University Medical Center | Nashville | United States | 427 |